Pre-Made Bevifimod biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Staphylococcal protein A for drug discovery and mechanism of action (MOA) research

Pre-Made Bevifimod biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Staphylococcal protein A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Preferred Name: Bevifimod Definition: A proprietary formulation containing a highly purified form of Staphylococcal protein A (SpA; protein A), with potential immunomodulating activity. Upon administration of bevifimod, this protein is able to specifically bind to both the subset of B-lymphocytes that express the heavy chain variable region 3 (VH3)-encoded immunoglobulin (Ig) (VH3-B-cells) and macrophages. This prevents B-cell activation, induces apoptosis, prevents VH3-derived antibody formation, antibody-mediated immune responses, and destruction by macrophages. This may modulate specific immune signaling pathways and restore normal immune system functions caused by certain immune-mediated inflammatory diseases. In patients with the autoimmune-mediated disease immune thrombocytopenia (ITP), PRTX-100 prevents destruction of platelets, increases platelet production and platelet blood levels, and decreases the risk of bleeding. SpA, a 42 kDa bacterial membrane protein produced by Staphylococcus aureus bacteria, consists of five nearly identical Ig binding domains; each SpA domain binds with high affinity to the Igs containing regions encoded by the VH3 gene family. B-lymphocytes that express VH3-encoded Igs are specifically involved in various auto-immune diseases.

Immunoglobulin (Ig) G molecules are essential players in the human immune response against bacterial infections. An important effector of IgG-dependent immunity is the induction of complement activation, a reaction that triggers a variety of responses that help kill bacteria. Antibody-dependent complement activation is promoted by the organization of target-bound IgGs into hexamers that are held together via noncovalent Fc-Fc interactions. BEVIFIMOD, staphylococcal protein A (SpA) is an important virulence factor and vaccine candidate of Staphylococcus aureus, effectively blocks IgG hexamerization and subsequent complement activation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-758-1mg	1mg	3090
GMP-Bios-INN-758-10mg	10mg	Inquiry
GMP-Bios-INN-758-100mg	100mg	Inquiry
GMP-Bios-INN-758-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Bevifimod biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Staphylococcal protein A
INN Name	Bevifimod
Target	Staphylococcal protein A
Format	Recombinant Protein
Derivation	Staphylococcus aureus
Species Reactivity	human
CH1 Isotype	staphylococcal protein A (SpA)
VD LC	staphylococcal protein A (SpA)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Protalex, Inc. (Florham Park NJ USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0